Goods & Services

Cancer screening test comprised of molecular diagnostic reagents for detecting DNA, protein, methylation and/or chromosomal changes, abnormalities or mutations; diagnostic test consisting of buffers and reagents for use in cancer testing; reagents for medical use; medical diagnostic reagents. Medical laboratory services in the field of cancer. Providing medical diagnostic services, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories and medical diagnostic testing in the field of cancer; providing genomic and genetic testing for medical purposes in the field of cancer; medical testing services, namely, genetic testing and next generation sequencing test for diagnosis and treatment of cancer; providing medical information to medical professionals, namely, oncologists and treating physicians for cancer patients, in the form of reports in the field of cancer screening, diagnostics, prognostics and treatment.

Goods & Services

Cancer screening test comprised of molecular diagnostic reagents for detecting DNA, protein, methylation and/or chromosomal changes, abnormalities or mutations; diagnostic test consisting of buffers and reagents for use in cancer testing; reagents for medical use; medical diagnostic reagents. Medical laboratory services in the field of cancer. Providing medical diagnostic services, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories and medical diagnostic testing in the field of cancer; providing genomic and genetic testing for medical purposes in the field of cancer; medical testing services, namely, genetic testing and next generation sequencing test for diagnosis and treatment of cancer; providing medical information to medical professionals, namely, oncologists and treating physicians for cancer patients, in the form of reports in the field of cancer screening, diagnostics, prognostics and treatment.

Goods & Services

Cancer screening test comprised of molecular diagnostic reagents for detecting DNA, protein, methylation and/or chromosomal changes, abnormalities or mutations; diagnostic test consisting of buffers and reagents for use in cancer testing; reagents for medical use; medical diagnostic reagents. Medical laboratory services in the field of cancer. Providing medical diagnostic services, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories and medical diagnostic testing in the field of cancer; providing genomic and genetic testing for medical purposes in the field of cancer; medical testing services, namely, genetic testing and next generation sequencing test for diagnosis and treatment of cancer; providing medical information to medical professionals, namely, oncologists and treating physicians for cancer patients, in the form of reports in the field of cancer screening, diagnostics, prognostics and treatment.

Abstract

A method for detecting a methylated genomic locus is provided. In certain embodiments, the method comprises: a) treating a nucleic acid sample that contains both unmethylated and methylated copies of a genomic locus with an agent that modifies cytosine to uracil to produce a treated nucleic acid; b) amplifying a product from the treated nucleic acid using a first primer and a second primer, wherein the first primer hybridizes to a site in the locus that contain methylcytosines and the amplifying preferentially amplifies the methylated copies of the genomic locus, to produce an amplified sample; and c) detecting the presence of amplified methylated copies of the genomic locus in the amplified sample using a flap assay that employs an invasive oligonucleotide having a 3′ terminal G or C nucleotide that corresponds to a site of methylation in the genomic locus.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

e.g.e.g., blood samples, for analysis.

IPC Classes  ?

• B01L 9/06 - Test-tube standsTest-tube holders
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Goods & Services

Cancer screening test comprised of molecular diagnostic reagents for detecting DNA, protein, methylation and/or chromosomal changes, abnormalities or mutations; diagnostic test consisting of buffers and reagents for use in cancer testing; reagents for medical use; medical diagnostic reagents Medical laboratory services in the field of cancer Providing medical diagnostic services, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories and medical diagnostic testing in the field of cancer; Providing genomic and genetic testing for medical purposes in the field of cancer; Medical testing services, namely, genetic testing and next generation sequencing test for diagnosis and treatment of cancer; Providing medical information to medical professionals, namely, oncologists and treating physicians for cancer patients, in the form of reports in the field of cancer screening, diagnostics, prognostics and treatment

Goods & Services

Cancer screening test comprised of molecular diagnostic reagents for detecting DNA, protein, methylation and/or chromosomal changes, abnormalities or mutations; diagnostic test consisting of buffers and reagents for use in cancer testing; reagents for medical use; medical diagnostic reagents Medical laboratory services in the field of cancer Providing medical diagnostic services, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories and medical diagnostic testing in the field of cancer; Providing genomic and genetic testing for medical purposes in the field of cancer; Medical testing services, namely, genetic testing and next generation sequencing test for diagnosis and treatment of cancer; Providing medical information to medical professionals, namely, oncologists and treating physicians for cancer patients, in the form of reports in the field of cancer screening, diagnostics, prognostics and treatment

Abstract

Provided herein is technology relating to multiplex preamplification of multiple different target nucleic acids from a sample, e.g., an environmental or biological sample, and particularly, but not exclusively, to methods, compositions, kits, and related uses for detecting and assessing mixtures of target nucleic acids, e.g.. The technology provides methods, compositions, and kits for using low-bias amplification conditions to perform highly-multiplexed preamplification followed by highly-multiplexed detection assays such as PCR assays, next generation sequencing assays, and PCR-flap assay for assaying samples that comprise multiple different target nucleic acids.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

Provided herein is technology for breast cancer screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of breast cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6811 - Selection methods for production or design of target specific oligonucleotides or binding molecules
• C12Q 1/682 - Signal amplification
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

Provided herein is technology for breast cancer screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of breast cancer.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6811 - Selection methods for production or design of target specific oligonucleotides or binding molecules
• C12Q 1/682 - Signal amplification
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

Provided herein is technology for esophageal disorder screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of esophageal disorders (e.g., Barrett's esophagus, Barrett's esophageal dysplasia, etc.). In addition, the technology provides methods, compositions and related uses for distinguishing between Barrett's esophagus and Barrett's esophageal dysplasia, and between Barrett's esophageal low-grade dysplasia, Barrett's esophageal high-grade dysplasia, and esophageal adenocarcinoma within samples obtained through endoscopic brushing or nonendoscopic whole esophageal brushing or swabbing using a tethered device (e.g. such as a capsule sponge, balloon, or other device).

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Goods & Services

(1) Cancer screening test comprised of molecular diagnostic reagents for detecting DNA, protein, methylation and/or chromosomal changes, abnormalities or mutations; diagnostic test consisting of buffers and reagents for use in cancer testing; Reagents for medical use; Medical diagnostic reagents (1) Scientific and medical laboratory services in the field of cancer; Laboratory services, namely, liquid biopsy services for scientific research purposes using laboratory developed tests in the field of medical and scientific research in the field of cancer; Providing laboratory research services in the field of gene expression (2) Providing medical diagnostic services, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories and medical diagnostic testing in the field of cancer; Providing genomic and genetic testing for medical purposes in the field of cancer; Medical testing services, namely, genetic testing and next generation sequencing test for diagnosis and treatment of cancer; Providing medical information to medical professionals, namely, oncologists and treating physicians for cancer patients, in the form of reports in the field of cancer screening, diagnostics, prognostics and treatment

Abstract

Provided herein is technology relating to the amplification-based detection of nucleic acids and particularly, but not exclusively, to methods and compositions for minimizing variability in the activity between different samples or manufacturing lots of DNA polymerases, such as Taq DNA polymerase.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6851 - Quantitative amplification

Abstract

Provided herein is technology relating to the amplification-based detection of bisulfite-treated DNAs and particularly, but not exclusively, to methods and compositions for multiplex amplification of low-level sample DNA prior to further characterization of the sample DNA. The technology further provides methods for isolating DNA from blood or blood product samples, e.g., plasma samples.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]
• C01B 17/48 - Sulfur dioxideSulfurous acid
• C12N 15/65 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression using markers
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism

Abstract

A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases. The invention also relates to methods for identifying, diagnosing, staging or otherwise characterizing cancers, in particular gastrointestinal cancers such as colorectal cancers, gastric cancers and oesophageal cancers. The methods of the invention relate, inter alia, to isolating and analyzing the human DNA component from faecal samples and blood-based samples.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present disclosure provides borane reducing reagents, and in particular borane reducing reagents for use in methylation detection assays that comprise a step of reducing 5-formylcytosine (5fC) and/or 5-carboxylcytosine (5caC) to dihydrouracil (DHU).

IPC Classes  ?

• C07D 213/89 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12Q 1/6869 - Methods for sequencing
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Methods and kits directed to processing a fresh fecal sample from a human subject by a process comprising removing a portion of a collected fecal sample and adding the removed portion of the sample to a buffer that prevents denaturation or degradation of blood proteins, and stabilizing the remaining portion of the fecal sample with a stabilizing buffer that maintains nucleic acid integrity.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Provided herein is technology relating to the amplification-based detection of bisulfite-treated DNAs and particularly, but not exclusively, to methods and compositions for multiplex amplification of low-level sample DNA prior to further characterization of the sample DNA. The technology further provides methods for isolating DNA from blood or blood product samples, e.g., plasma samples.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

e.g.e.g., nucleic acid samples from subjects, in particular by characterizing marker-specific identifiers produced in multiplexed flap cleavage assays of the nucleic acid samples.

IPC Classes  ?

• C12Q 1/6811 - Selection methods for production or design of target specific oligonucleotides or binding molecules
• C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
• C12Q 1/6855 - Ligating adaptors
• C12Q 1/6869 - Methods for sequencing

Abstract

Methods and kits directed to processing a fresh fecal sample from a human subject by a process comprising removing a portion of a collected fecal sample and adding the removed portion of the sample to a buffer that prevents denaturation or degradation of blood proteins, and stabilizing the remaining portion of the fecal sample with a stabilizing buffer that maintains nucleic acid integrity.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Goods & Services

Providing information to patients in the field of medical diagnostic screening; providing medical information; providing medical diagnostic services, namely, medical analysis services for screening and diagnostic purposes provided by medical laboratories and medical diagnostic testing; providing information in the field of cancer screening

Goods & Services

Clinical medical reagents for diagnostic use; medical diagnostic reagents; colorectal cancer screening test kit comprised of molecular medical diagnostic reagents for detecting abnormal biomarkers in blood from cancer or pre-cancerous colon polyps Blood testing diagnostic apparatus for the detection of disease, namely, cancer, precancer, and diseases or conditions that predispose an individual to cancer; blood testing apparatus for medical diagnostic testing in the fields of cancer or other blood-based diagnostic testing; blood testing apparatus; kits for collecting blood samples comprised primarily of blood testing apparatus, namely, blood collecting tubes and also including stabilization buffers; containers for collecting blood samples for medical purposes; colorectal cancer screening test kit comprised primarily of blood drawing apparatus and also including containers for storing patient blood samples for analysis Scientific laboratory services in the field of cancer Providing information to patients in the field of medical diagnostic screening; providing medical information; providing medical diagnostic services, namely, medical analysis services for screening and diagnostic purposes provided by medical laboratories and medical diagnostic testing; providing information in the field of cancer screening; medical laboratory analysis services in the field of cancer relating to the treatment of persons

Abstract

Provided herein is technology for lung neoplasia screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of lung cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Methods and kits directed to processing a fresh fecal sample from a human subject by a process comprising removing a portion of a collected fecal sample and adding the removed portion of the sample to a buffer that prevents denaturation or degradation of blood proteins, and stabilizing the remaining portion of the fecal sample with a stabilizing buffer that maintains nucleic acid integrity.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Provided herein is technology relating compositions and methods for detecting tissue cell-specific DNA, such as epithelial cell-specific DNA, in blood or blood products from a subject. The technology also relates to use of tissue cell-specific DNAs as internal controls for methylation assays.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes

Abstract

Provided herein is technology for neoplasia screening, and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of cancer, in particular, colorectal cancer.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/533 - Production of labelled immunochemicals with fluorescent label
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G16Z 99/00 - Subject matter not provided for in other main groups of this subclass

Abstract

Provided herein is reagent mixture comprising multiplexed amplification reagents and flap assay reagents for detecting, in a single reaction, mutant copies of the KRAS gene that contain any of the 34A, 34C, 34T, 35A, 35C, 35T or 38A point mutations. Methods that employ the reagent mix and kits for performing the same are also provided.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6858 - Allele-specific amplification

Abstract

Provided herein is technology relating to collecting and preparing samples. For example, the technology relates particularly, but not exclusively, to devices, systems, and kits that allow a subject to collect and prepare a sample for analysis.

IPC Classes  ?

• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 1/38 - Diluting, dispersing or mixing samples

Abstract

Provided herein is technology relating to the amplification-based detection of nucleic acids and particularly, but not exclusively, to methods and compositions for minimizing variability in the activity between different samples or manufacturing lots of DNA polymerases, such as Taq DNA polymerase.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6851 - Quantitative amplification

Abstract

A stool resuspension solution comprising a hemoglobin stabilization reagent is provided. In some embodiments, the hemoglobin stabilization reagent may be an osmolyte, a polyvalent cation, a sugar or polysaccharide and, optionally, a polyvalent cation, a protoporphyrin, or an HRP stabilization component and, optionally, a polyvalent cation. A method of stabilizing hemoglobin in a stool sample in the solution is also provided, as well as a sample collection device containing the solution.

IPC Classes  ?

• G01N 33/72 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood pigments, e.g. hemoglobin, bilirubin
• G01N 1/38 - Diluting, dispersing or mixing samples
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Goods & Services

Preparations for detecting genetic predispositions for medical purposes, namely, hereditary cancer screening test comprised of molecular diagnostic reagents and assays for use in disease detection by detecting DNA, chromosomal changes, abnormalities or mutations for detection of genes for hereditary cancer, identifying hereditary risk associated with cancer and identifying predisposition to cancer; Reagents for medical use; Medical diagnostic assays for testing of body fluids; Medical diagnostic reagents; Medical diagnostic assays for use in disease detection and screening related to cancer

Goods & Services

Diagnostic apparatus for the detection of cancer by detecting genes for hereditary cancer, identifying hereditary risk associated with cancer and identifying predisposition to cancer; Apparatus for collecting biological samples, namely, blood or saliva, for use in the detection of cancer and pre-cancer for medical purposes by detecting genes for hereditary cancer, identifying hereditary risk associated with cancer and identifying predisposition to cancer; Saliva collection devices and blood collecting tubes for use in the detection of cancer and pre-cancer for medical purposes by detecting genes for hereditary cancer, identifying hereditary risk associated with cancer and identifying predisposition to cancer Medical testing services, namely, genetic testing and next generation sequencing test for diagnosis and treatment of cancer featuring detection of genes for hereditary cancer, identification of hereditary risk associated with cancer and identification of predisposition to cancer

Goods & Services

Preparations for detecting genetic predispositions for medical purposes, namely, hereditary cancer screening test comprised of molecular diagnostic reagents and assays for use in disease detection by detecting DNA, chromosomal changes, abnormalities or mutations for detection of genes for hereditary cancer, identifying hereditary risk associated with cancer and identifying predisposition to cancer; Reagents for medical use; medical diagnostic assays for testing of body fluids; Medical diagnostic reagents; Medical diagnostic assays for use in disease detection and screening related to cancer

Goods & Services

Diagnostic apparatus for the detection of cancer by detecting genes for hereditary cancer, identifying hereditary risk associated with cancer and identifying predisposition to cancer; Apparatus for collecting biological samples for use in the detection of cancer and pre-cancer for medical purposes by detecting genes for hereditary cancer, identifying hereditary risk associated with cancer and identifying predisposition to cancer; Containers for collecting biological samples for use in the detection of cancer and pre-cancer for medical purposes by detecting genes for hereditary cancer, identifying hereditary risk associated with cancer and identifying predisposition to cancer Medical testing services, namely, genetic testing and next generation sequencing testing for diagnosis and treatment of cancer featuring detection of genes for hereditary cancer, identification of hereditary risk associated with cancer and identification of predisposition to cancer

Abstract

The present invention relates to methods and compositions for determination of and uses of specific methylation patterns indicative of adenoma and carcinoma. In particular, the invention relates to analysis of defined CpG loci that are coordinately methylated in DNAs from cancer and adenoma samples, methods for identifying coordinately methylated loci, and methods of using analysis of coordinately methylated loci in one or more marker regions in the design of assays for adenoma and cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/6858 - Allele-specific amplification

Abstract

Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as colorectal cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

A method of detecting a predisposition to, or the incidence of, colorectal cancer in a fecal sample comprises, in a first step (a), detecting the presence of blood in the fecal sample, wherein detection of the presence of blood is indicative of a predisposition to, or the incidence of, colorectal cancer. The method additionally comprises, in second step (b), detecting an epigenetic modification in the DNA contained within the fecal sample, wherein detection of the epigenetic modification is indicative of a predisposition to, or the incidence of, colorectal cancer. Based upon a positive result obtained in either (a) or (b) or in both (a) and (b) a predisposition to, or the incidence of, colorectal cancer is detected. Related methods and kits involve detecting an epigenetic modification in a number of specific genes.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention provides synthetic DNA strands that find use as process controls in DNA processing and nucleic acid testing methods. In particular, provided herein are synthetic methylated DNA strands of known composition for use as control molecules in DNA testing, e.g., of mutations and/or methylation of DNA isolated from non-fish samples, such as human samples.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

Methods and compositions for detection and measuring target nucleic acid molecules using a FEN-1 endonuclease to cleave a FEN-1 substrate padlock probe in the presence of the target nucleic acid, with ligation to form a circularized probe. The technology further pertains to detection of circularized probes using, e.g., rolling circle amplification.

IPC Classes  ?

• C12Q 1/682 - Signal amplification

Abstract

A method of sample analysis is provided. In certain embodiments, the method involves: a) amplifying a product from a sample that comprises both wild type copies of a genomic locus and mutant copies of the genomic locus that have a point mutation relative to said wild type copies of the genomic locus, to produce an amplified sample, where: i. the amplifying is done using a first primer and a second primer; and ii. the first primer comprises a 3′ terminal nucleotide that base pairs with the point mutation and also comprises a nucleotide sequence that is fully complementary to a sequence in the locus with the exception of a single base mismatch within 6 bases of the 3′ terminal nucleotide; and b) detecting the presence of said product in said amplified sample using a flap assay that employs an invasive oligonucleotide. A kit for performing the method is also provided.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6858 - Allele-specific amplification
• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes

Abstract

Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as gastric cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Provided herein is technology for ovarian cancer screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of ovarian cancer and sub-types of ovarian cancer (e.g., clear cell ovarian cancer, endometrioid ovarian cancer, mucinous ovarian cancer, serous ovarian cancer).

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
• C12Q 1/6869 - Methods for sequencing
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as pancreatic and colorectal cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Provided herein is technology relating to collecting and containing samples and particularly, but not exclusively, to technology for collecting and containing a stool specimen. The technology provides a device for collecting and containing a stool specimen, the device comprising ergonomic features optimized for a geriatric user. The technology also provides an enclosing holder for securing the ergonomic stool specimen container in a leak-proof manner e.g., during mechanical shaking.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• G01N 1/38 - Diluting, dispersing or mixing samples

Abstract

The present disclosure relates to detecting one or more types of urological cancer in a biological sample from a subject. In particular, the present disclosure provides compositions and methods for detecting the presence or absence of one or more types of urological cancer (e.g., urothelial cancer and/or renal cell carcinoma) in a biological sample from a subject having or suspected of having a urological cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Provided herein is technology related to the chemical modification and purification of DNA. Specifically, the technology provides methods for performing a bisulfite conversion reaction on small amounts of single-stranded, fragmented DNA and performing the subsequent desulfonation and purification steps on magnetic beads.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6851 - Quantitative amplification

Goods & Services

Platform as a service (PAAS) services featuring a computer software platform that allows patients to communicate with healthcare providers, doctors, and physicians, access on-demand phone support, and receive reminder phone calls, texts and emails in the field of cancer screening, pre-cancer screening, cancer diagnostic testing, disease or pre-disease detection, monitoring or surveillance; Providing temporary online use of non-downloadable software for use by physicians for use in collecting, requesting, managing, analyzing and comparing medical information, patient records, patient laboratory orders, patient tests and analysis; Providing an online website portal featuring technology that allows users to register and access the test results associated with medical and diagnostic test kits for detecting cancer; all of the foregoing for use in the field of cancer diagnostics, prognostics and treatment recommendations; Platform as a service (PAAS) services featuring a computer software platform for lab systems automation and for accessing electronic medical records; Providing a secured-access website featuring technology that allows registered users the ability to send and receive information and to share documents, images and information in the fields of health, genomics, cancer, cancer treatments and personalized medicine; Computer services, namely, providing a website featuring technology that automates the publication of research and information pertaining to health, genomics, cancer, treatment of cancer, and personalized medicine; Cloud storage services for electronic data and electronic files

Abstract

A device for collecting a metered sample from specimen material, particularly soft or semisolid materials such as stool, foods, soil, environmental, and/or industrial materials, and methods and kits for using the technology for collection of metered samples of material for analysis.

IPC Classes  ?

• G01N 1/04 - Devices for withdrawing samples in the solid state, e.g. by cutting
• C12M 1/26 - Inoculator or sampler
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• A61B 10/02 - Instruments for taking cell samples or for biopsy

Goods & Services

Clinical medical reagents for diagnostic use; medical diagnostic reagents; colorectal cancer screening test kit comprised of molecular diagnostic reagents for detecting abnormal DNA in stool from cancer or pre-cancerous colon polyps. Diagnostic apparatus for the detection of disease; apparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testing, cytology and cell-based testing; apparatus and kits for collecting biological samples comprised of stool collection container, holder for stool collection container, stool sampling device, stool sample transport tube, and protein stabilization buffers; containers for collecting biological samples for medical purposes; colorectal cancer screening test kit comprised of implements and container for collecting patient stool samples for analysis. Providing scientific and medical laboratory services in the field of cancer. Providing information to patients in the field of medical diagnostic screening; providing medical information; providing medical diagnostic services, namely, medical analysis services for screening and diagnostic purposes provided by medical laboratories and medical diagnostic testing; providing information in the field of cancer screening.

Goods & Services

Clinical medical reagents for diagnostic use; medical diagnostic reagents; colorectal cancer screening test kit comprised of molecular diagnostic reagents for detecting abnormal DNA in stool from cancer or pre-cancerous colon polyps. Diagnostic apparatus for the detection of disease; apparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testing, cytology and cell-based testing; apparatus and kits for collecting biological samples comprised of stool collection container, holder for stool collection container, stool sampling device, stool sample transport tube, and protein stabilization buffers; containers for collecting biological samples for medical purposes; colorectal cancer screening test kit comprised of implements and container for collecting patient stool samples for analysis. Providing scientific and medical laboratory services in the field of cancer. Providing information to patients in the field of medical diagnostic screening; providing medical information; providing medical diagnostic services, namely, medical analysis services for screening and diagnostic purposes provided by medical laboratories and medical diagnostic testing; providing information in the field of cancer screening.

Goods & Services

Clinical medical reagents for diagnostic use; medical diagnostic reagents; colorectal cancer screening test kit comprised of molecular diagnostic reagents for detecting abnormal DNA in stool from cancer or pre-cancerous colon polyps. Diagnostic apparatus for the detection of disease; apparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testing, cytology and cell-based testing; apparatus and kits for collecting biological samples comprised of stool collection container, holder for stool collection container, stool sampling device, stool sample transport tube, and protein stabilization buffers; containers for collecting biological samples for medical purposes; colorectal cancer screening test kit comprised of implements and container for collecting patient stool samples for analysis. Providing scientific and medical laboratory services in the field of cancer. Providing information to patients in the field of medical diagnostic screening; providing medical information; providing medical diagnostic services, namely, medical analysis services for screening and diagnostic purposes provided by medical laboratories and medical diagnostic testing; providing information in the field of cancer screening.

Goods & Services

Clinical medical reagents for diagnostic use; medical diagnostic reagents; colorectal cancer screening test kit comprised of molecular diagnostic reagents for detecting abnormal DNA in stool from cancer or pre-cancerous colon polyps. Diagnostic apparatus for the detection of disease; apparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testing, cytology and cell-based testing; apparatus and kits for collecting biological samples comprised of stool collection container, holder for stool collection container, stool sampling device, stool sample transport tube, and protein stabilization buffers; containers for collecting biological samples for medical purposes; colorectal cancer screening test kit comprised of implements and container for collecting patient stool samples for analysis. Providing scientific and medical laboratory services in the field of cancer. Providing information to patients in the field of medical diagnostic screening; providing medical information; providing medical diagnostic services, namely, medical analysis services for screening and diagnostic purposes provided by medical laboratories and medical diagnostic testing; providing information in the field of cancer screening.

Abstract

The present disclosure provides methods and systems for purification of chemically modified, specifically, sulfonated DNA. Additionally, the disclosure provides methods and systems for bisulfite conversion with improved purification of sulfonated DNA using silica supports, such as silica beads, and acidic conditions for binding sulfonated DNA to silica surfaces.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

Provided herein is technology relating to isolating nucleic acids. In particular, the technology relates to methods and kits for extracting nucleic acids from problematic samples such as stool.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• B01D 33/15 - Filters with filtering elements which move during the filtering operation with rotary plane filtering surfaces
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• B03C 1/30 - Combinations with other devices, not otherwise provided for
• B04B 3/00 - Centrifuges with rotary bowls in which solid particles or bodies become separated by centrifugal force and simultaneously sifting or filtering
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Methods, compositions, and systems for testing fecal samples, including small human fecal samples, for a plurality of different marker analytes, e.g., a plurality of different human protein, nucleic acid, and other molecular marker analytes.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Provided herein is technology for prostate cancer screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of prostate cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

A method for detecting a methylated genomic locus is provided. In certain embodiments, the method comprises: a) treating a nucleic acid sample that contains both unmethylated and methylated copies of a genomic locus with an agent that modifies cytosine to uracil to produce a treated nucleic acid; b) amplifying a product from the treated nucleic acid using a first primer and a second primer, wherein the first primer hybridizes to a site in the locus that contain methylcytosines and the amplifying preferentially amplifies the methylated copies of the genomic locus, to produce an amplified sample; and c) detecting the presence of amplified methylated copies of the genomic locus in the amplified sample using a flap assay that employs an invasive oligonucleotide having a 3′ terminal G or C nucleotide that corresponds to a site of methylation in the genomic locus.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Goods & Services

(1) Clinical medical reagents for diagnostic use; medical diagnostic reagents; colorectal cancer screening test kit comprised of molecular diagnostic reagents for detecting abnormal DNA in stool from cancer or pre-cancerous colon polyps. (2) Medical diagnostic apparatus for detecting biomarkers in blood, tissue and stool samples for the detection of disease; Medical diagnostic apparatus for medical diagnostic testing in the fields of cancer, namely, stool-based cancer detection; apparatus and kits for collecting biological samples comprised of stool collection container, holder for stool collection container, stool sampling device, stool sample transport tube, and protein stabilization buffers; containers for collecting biological samples for medical purposes; colorectal cancer screening test kit comprised of implements and container for collecting patient stool samples for analysis. (1) Providing scientific and medical laboratory services in the field of cancer, namely, providing cancer screening services. (2) Providing information to patients in the field of medical diagnostic screening; providing medical information in the field of oncology; providing medical diagnostic services, namely, medical analysis services for screening and diagnostic purposes provided by medical laboratories and medical diagnostic testing; providing information in the field of cancer screening.

Goods & Services

(1) Clinical medical reagents for diagnostic use; medical diagnostic reagents; colorectal cancer screening test kit comprised of molecular diagnostic reagents for detecting abnormal DNA in stool from cancer or pre-cancerous colon polyps. (2) Medical diagnostic apparatus for detecting biomarkers in blood, tissue and stool samples for the detection of disease; Medical diagnostic apparatus for medical diagnostic testing in the fields of cancer, namely, stool-based cancer detection; apparatus and kits for collecting biological samples comprised of stool collection container, holder for stool collection container, stool sampling device, stool sample transport tube, and protein stabilization buffers; containers for collecting biological samples for medical purposes; colorectal cancer screening test kit comprised of implements and container for collecting patient stool samples for analysis. (1) Providing scientific and medical laboratory services in the field of cancer, namely, providing cancer screening services. (2) Providing information to patients in the field of medical diagnostic screening; providing medical information in the field of oncology; providing medical diagnostic services, namely, medical analysis services for screening and diagnostic purposes provided by medical laboratories and medical diagnostic testing; providing information in the field of cancer screening.

Goods & Services

(1) Clinical medical reagents for diagnostic use; medical diagnostic reagents; colorectal cancer screening test kit comprised of molecular diagnostic reagents for detecting abnormal DNA in stool from cancer or pre-cancerous colon polyps. (2) Medical diagnostic apparatus for detecting biomarkers in blood, tissue and stool samples for the detection of disease; Medical diagnostic apparatus for medical diagnostic testing in the fields of cancer, namely, stool-based cancer detection; apparatus and kits for collecting biological samples comprised of stool collection container, holder for stool collection container, stool sampling device, stool sample transport tube, and protein stabilization buffers; containers for collecting biological samples for medical purposes; colorectal cancer screening test kit comprised of implements and container for collecting patient stool samples for analysis. (1) Providing scientific and medical laboratory services in the field of cancer, namely, providing cancer screening services. (2) Providing information to patients in the field of medical diagnostic screening; providing medical information in the field of oncology; providing medical diagnostic services, namely, medical analysis services for screening and diagnostic purposes provided by medical laboratories and medical diagnostic testing; providing information in the field of cancer screening.

Goods & Services

(1) Clinical medical reagents for diagnostic use; medical diagnostic reagents; colorectal cancer screening test kit comprised of molecular diagnostic reagents for detecting abnormal DNA in stool from cancer or pre-cancerous colon polyps. (2) Medical diagnostic apparatus for detecting biomarkers in blood, tissue and stool samples for the detection of disease; Medical diagnostic apparatus for medical diagnostic testing in the fields of cancer, namely, stool-based cancer detection; apparatus and kits for collecting biological samples comprised of stool collection container, holder for stool collection container, stool sampling device, stool sample transport tube, and protein stabilization buffers; containers for collecting biological samples for medical purposes; colorectal cancer screening test kit comprised of implements and container for collecting patient stool samples for analysis. (1) Providing scientific and medical laboratory services in the field of cancer, namely, providing cancer screening services. (2) Providing information to patients in the field of medical diagnostic screening; providing medical information in the field of oncology; providing medical diagnostic services, namely, medical analysis services for screening and diagnostic purposes provided by medical laboratories and medical diagnostic testing; providing information in the field of cancer screening.

Abstract

Provided herein is technology relating to the amplification-based detection of bisulfite-treated DNAs and particularly, but not exclusively, to methods and compositions for multiplex amplification of low-level sample DNA prior to further characterization of the sample DNA. The technology further provides methods for isolating DNA from blood or blood product samples, e.g., plasma samples.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips

Abstract

The present invention provides synthetic DNA strands that find use as controls or in nucleic acid testing methods. In particular, provided herein are synthetic DNA strands of known composition for use as control molecules in stool DNA testing, e.g., of mutations and/or methylation of DNA isolated from stool samples.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

e.g.e.g.e.g.. The technology provides methods, compositions, and kits for using low-bias amplification conditions to perform highly-multiplexed preamplification followed by highly-multiplexed detection assays such as PCR assays, next generation sequencing assays, and PCR-flap assay for assaying samples that comprise multiple different target nucleic acids.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6869 - Methods for sequencing

Abstract

A method of processing a fecal sample from a human subject comprising combining a first portion of a collected fecal sample with a stabilizing buffer, combining a second portion of the sample with a solution that prevents denaturation or degradation of blood proteins found in a fecal sample. Embodiments comprise testing nucleic acid extracted from the first portion of the fecal sample for an amount of a human nucleic acid, and testing the second portion of the fecal sample for the presence of human blood.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present disclosure provides compositions and methods related to TET-assisted oxidation of methylated nucleotide bases. In particular, the present disclosure provides optimized oxidation methods which provide more efficient and complete oxidation. The disclosed methods may be used to identify and detect the methylated nucleotide bases, particularly in conjunction with known TET-assisted sequencing methods.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12Q 1/6869 - Methods for sequencing
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

Methods are provided for conducting an assay on a set of nucleic acid targets, including: combining a set of dual probes with a sample composition potentially comprising a set of nucleic acid targets to form a set of cleavable ternary nucleic acid complexes; releasing from the cleavable ternary nucleic acid complex a set of recognition element fragments comprising the recognition element sequence; combining the released recognition element fragments with an additional nucleic acid sequence from a set of additional nucleic acid sequences to create a circular nucleic acid, wherein the circular nucleic acid comprises a target-associated code and additional sequence elements; and performing a detection event to identify a set of detected codes of the target-associated codes.

IPC Classes  ?

• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12N 9/22 - Ribonucleases
• C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 30/20 - Sequence assembly

Goods & Services

(1) Providing a website featuring resources, namely, non-downloadable videos and publications in the nature of newsletters and articles in the field of cancer; Providing an internet website portal featuring non-downloadable educational videos and webcasts in the field of cancer (2) Platform as a service (PAAS) services featuring a computer software platform that allows patients to communicate with healthcare providers, doctors, and physicians, access on-demand phone support, and receive reminder phone calls, texts and emails in the field of cancer screening, pre-cancer screening, cancer diagnostic testing, disease or pre-disease detection, monitoring or surveillance; Providing temporary online use of non-downloadable software for use by physicians for use in collecting, requesting, managing, analyzing and comparing medical information, patient records, patient laboratory orders, patient tests and analysis; Providing an online website portal featuring technology that allows users to register and access the test results associated with medical and diagnostic test kits for detecting cancer; all of the foregoing for use in the field of cancer diagnostics, prognostics and treatment recommendations (3) Providing medical information to medical professionals and healthcare providers in the form of reports in the field of cancer screening, diagnostics, prognostics and treatment; Providing information to patients in the field of medical diagnostic screening; Providing medical information in the field of cancer awareness; Providing information in the field of prevention, screening, diagnosis, and treatment of cancer; Providing information to patients, medical professionals and healthcare providers in the field of medical diagnostic screening; Providing medical information; Providing a web site featuring medical information; Providing medical diagnostic services, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories and medical diagnostic testing in the field of cancer; Providing genomic and genetic testing for medical purposes in the field of cancer; Medical testing services, namely, genetic testing and next generation sequencing test for diagnosis and treatment of cancer; Medical testing for diagnostic and prognostic purposes and therapy selection in the field of cancer and disease classification; Medical testing for diagnostic and treatment purposes in the field of cancer research and disease classification; Medical testing services, namely, genetic testing and next generation sequencing test for diagnosis and treatment of cancer featuring detection of genes and copy number variations for hereditary cancer, identification of hereditary risk associated with cancer and identification of predisposition to cancer

Goods & Services

Providing a website featuring resources, namely, non-downloadable videos and publications in the nature of newsletters and articles in the field of cancer; Providing an internet website portal featuring non-downloadable educational videos and webcasts in the field of cancer. Platform as a service (PAAS) services featuring a computer software platform that allows patients to communicate with healthcare providers, doctors, and physicians, access on-demand phone support, and receive reminder phone calls, texts and emails in the field of cancer screening, pre-cancer screening, cancer diagnostic testing, disease or pre-disease detection, monitoring or surveillance; Providing temporary online use of non-downloadable software for use by physicians for use in collecting, requesting, managing, analyzing and comparing medical information, patient records, patient laboratory orders, patient tests and analysis; Providing an online website portal featuring technology that allows users to register and access the test results associated with medical and diagnostic test kits for detecting cancer; all of the foregoing for use in the field of cancer diagnostics, prognostics and treatment recommendations. Providing medical information to medical professionals and healthcare providers in the form of reports in the field of cancer screening, diagnostics, prognostics and treatment; Providing information to patients in the field of medical diagnostic screening; Providing medical information in the field of cancer awareness; Providing information in the field of prevention, screening, diagnosis, and treatment of cancer; Providing information to patients, medical professionals and healthcare providers in the field of medical diagnostic screening; Providing medical information; Providing a web site featuring medical information; Providing medical diagnostic services, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories and medical diagnostic testing in the field of cancer; Providing genomic and genetic testing for medical purposes in the field of cancer; Medical testing services, namely, genetic testing and next generation sequencing test for diagnosis and treatment of cancer; Medical testing for diagnostic and prognostic purposes and therapy selection in the field of cancer and disease classification; Medical testing for diagnostic and treatment purposes in the field of cancer research and disease classification; Medical testing services, namely, genetic testing and next generation sequencing test for diagnosis and treatment of cancer featuring detection of genes and copy number variations for hereditary cancer, identification of hereditary risk associated with cancer and identification of predisposition to cancer.

Abstract

A method of processing a fecal sample from a human subject comprising combining a first portion of a collected fecal sample with a stabilizing buffer that maintains DNA integrity in a fecal sample, and combining a second portion of the sample with a solution that prevents denaturation or degradation of blood proteins found in a fecal sample. Embodiments comprise testing DNA extracted from the first portion of the fecal sample for the presence of a human DNA, and testing the second portion of the fecal sample for the presence of human blood.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Methods are provided for conducting a dual-probe assay on a set of nucleic acid targets, including: combining a set of dual probes with a sample composition potentially comprising a set of nucleic acid targets to form a set of cleavable ternary nucleic acid complexes; releasing from the cleavable ternary nucleic acid complex a set of recognition element fragments; hybridizing each of the set of released recognition element fragments to a coded oligonucleotide probe and using resulting hybridized released recognition elements as primers for copying the coded oligonucleotide probe to produce a sect of target-associated codes, wherein each of the coded oligonucleotide probes comprises a code from a set of codes, each code comprises at least one segment encoding one or more symbols that correspond to a sequence of one or more nucleotides; and performing a detection event to identify a set of detected codes of the target-associated codes.

IPC Classes  ?

• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12N 9/22 - Ribonucleases
• C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 30/20 - Sequence assembly

Goods & Services

Providing information to patients in the field of medical diagnostic screening; providing medical information; providing medical diagnostic services, namely, medical analysis services for screening and diagnostic purposes provided by medical laboratories and medical diagnostic testing; providing information in the field of cancer screening

Goods & Services

Clinical medical reagents for diagnostic use; medical diagnostic reagents; colorectal cancer screening test kit comprised of molecular diagnostic reagents for detecting abnormal DNA in stool from cancer or pre-cancerous colon polyps Diagnostic apparatus for the detection of disease, namely, cancer, precancer, or disease or condition that predisposes an individual to cancer; apparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testing, cytology and cell-based testing; apparatus and kits for collecting biological samples comprised of stool collection container, holder for stool collection container, stool sampling device, stool sample transport tube, and protein stabilization buffers; containers for collecting biological samples for medical purposes; Colorectal cancer screening test kit comprised of implements and container for collecting patient stool samples for analysis Providing scientific and medical laboratory services in the field of cancer

Abstract

A stool resuspension solution comprising a hemoglobin stabilization reagent is provided. In some embodiments, the hemoglobin stabilization reagent may be an osmolyte, a polyvalent cation, a sugar or polysaccharide and, optionally, a polyvalent cation, a protoporphyrin, or an HRP stabilization component and, optionally, a polyvalent cation. A method of stabilizing hemoglobin in a stool sample in the solution is also provided, as well as a sample collection device containing the solution.

IPC Classes  ?

• G01N 33/72 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood pigments, e.g. hemoglobin, bilirubin
• G01N 1/38 - Diluting, dispersing or mixing samples
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Goods & Services

Clinical medical reagents for diagnostic use; medical diagnostic reagents; colorectal cancer screening test kit comprised of molecular diagnostic reagents for detecting abnormal DNA in stool from cancer or pre-cancerous colon polyps Diagnostic apparatus for the detection of disease, namely, cancer, precancer, or disease or condition that predisposes an individual to cancer; apparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testing, cytology and cell-based testing; apparatus and kits for collecting biological samples comprised of stool collection container, holder for stool collection container, stool sampling device, stool sample transport tube, and protein stabilization buffers; containers for collecting biological samples for medical purposes; Colorectal cancer screening test kit comprised of implements and container for collecting patient stool samples for analysis Providing scientific and medical laboratory services in the field of cancer Providing information to patients in the field of medical diagnostic screening; providing medical information; providing medical diagnostic services, namely, medical analysis services for screening and diagnostic purposes provided by medical laboratories and medical diagnostic testing; providing information in the field of cancer screening

Abstract

The invention relates to cell sampling devices. In particular, the present invention relates to ingestible cell sampling devices for sampling cells in a subject, and methods of use for detecting abnormalities in a subject using the same.

IPC Classes  ?

• A61B 10/02 - Instruments for taking cell samples or for biopsy
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Goods & Services

Clinical medical reagents for diagnostic use; medical diagnostic reagents; colorectal cancer screening test kit comprised of molecular diagnostic reagents for detecting abnormal DNA in stool from cancer or pre-cancerous colon polyps Diagnostic apparatus for the detection of disease, namely, cancer, precancer, or disease or condition that predisposes an individual to cancer; apparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testing, cytology and cell-based testing; apparatus and kits for collecting biological samples comprised of stool collection container, holder for stool collection container, stool sampling device, stool sample transport tube, and protein stabilization buffers; containers for collecting biological samples for medical purposes; Colorectal cancer screening test kit comprised of implements and container for collecting patient stool samples for analysis Providing scientific and medical laboratory services in the field of cancer Providing information to patients in the field of medical diagnostic screening; providing medical information; providing medical diagnostic services, namely, medical analysis services for screening and diagnostic purposes provided by medical laboratories and medical diagnostic testing; providing information in the field of cancer screening

Goods & Services

Providing scientific and medical laboratory services in the field of cancer Providing information to patients in the field of medical diagnostic screening; providing medical information; providing medical diagnostic services, namely, medical analysis services for screening and diagnostic purposes provided by medical laboratories and medical diagnostic testing; providing information in the field of cancer screening

Goods & Services

Clinical medical reagents for diagnostic use; medical diagnostic reagents; colorectal cancer screening test kit comprised of molecular diagnostic reagents for detecting abnormal DNA in stool from cancer or pre-cancerous colon polyps Diagnostic apparatus for the detection of disease, namely, cancer, precancer, or disease or condition that predisposes an individual to cancer; apparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testing, cytology and cell-based testing; apparatus and kits for collecting biological samples comprised of stool collection container, holder for stool collection container, stool sampling device, stool sample transport tube, and protein stabilization buffers; containers for collecting biological samples for medical purposes; Colorectal cancer screening test kit comprised of implements and container for collecting patient stool samples for analysis

Abstract

A cleavage-based real-time PCR assay method is provided. In general terms, the assay method includes subjecting a reaction mixture comprising a) PCR reagents for amplifying a nucleic acid target, and b) flap cleavage reagents for performing a flap cleavage assay on the amplified nucleic acid target to two sets of thermocycling conditions. No additional reagents are added to the reaction between said first and second sets of cycles and, in each cycle of the second set of cycles, cleavage of a flap probe is measured.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6818 - Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Provided herein is technology for primary cutaneous melanoma screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of primary cutaneous melanoma.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6858 - Allele-specific amplification

Abstract

Provided herein is technology for lung neoplasia screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of lung cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

A method of processing a fecal sample from a human subject comprising removing a portion of a collected fecal sample and adding the removed portion of the sample to a buffer that prevents denaturation or degradation of blood proteins found in the sample, and detecting the presence of human blood in the removed portion of the fecal sample. The method further comprises stabilizing the remaining portion of the fecal sample.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

5′ hairpin oligonucleotide substrates for reversible repression, e.g., by temperature shift, of cleavage by flap endonucleases, and methods using 5′ hairpin oligonucleotides.

IPC Classes  ?

• C12Q 1/6818 - Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting neoplasms such as lung cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

A stool resuspension solution comprising a hemoglobin stabilization reagent is provided. In some embodiments, the hemoglobin stabilization reagent may be an osmolyte, a polyvalent cation, a sugar or polysaccharide and, optionally, a polyvalent cation, a protoporphyrin, or an HRP stabilization component and, optionally, a polyvalent cation. A method of stabilizing hemoglobin in a stool sample in the solution is also provided, as well as a sample collection device containing the solution.

IPC Classes  ?

• G01N 33/72 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood pigments, e.g. hemoglobin, bilirubin
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 1/38 - Diluting, dispersing or mixing samples

Abstract

Provided herein is technology for screening for esophageal disorders, including but not limited to, Barrett's esophagus (BE). In particular, provided herein are methods, compositions, and related uses for detecting the presence or absence of esophageal disorders from a biological sample.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

Provided herein is technology relating compositions and methods for analysis of methylated DNA from a subject. The technology also relates to use of endogenous methylated DNAs as internal controls for marker gene methylation assays.

IPC Classes  ?

• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism

Abstract

Provided herein is reagent mixture comprising multiplexed amplification reagents and flap assay reagents for detecting, in a single reaction, mutant copies of the KRAS gene that contain any of the 34A, 34C, 34T, 35A, 35C, 35T or 38A point mutations. Methods that employ the reagent mix and kits for performing the same are also provided.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6858 - Allele-specific amplification
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Goods & Services

Providing information to patients in the field of medical diagnostic screening; Providing medical information in the field of cancer awareness; Providing information in the field of prevention, screening, diagnosis, and treatment of cancer

Goods & Services

Hereditary cancer test comprised of molecular diagnostic reagents and assays for detecting DNA, chromosomal changes, abnormalities or mutations for detection of genes and copy number variations for hereditary cancer, identification of hereditary risk associated with cancer and identification of predisposition to cancer; Reagents and assays for medical use; Medical diagnostic reagents; Medical diagnostic assays.

Goods & Services

Diagnostic apparatus for the detection of genes and copy number variations, for hereditary cancer, identification of hereditary risk associated with cancer and identification of predisposition to cancer; Apparatus for collecting biological samples for use in detection of genes and copy number variations for hereditary cancer, identification of hereditary risk associated with cancer and identification of predisposition to cancer; Containers for collecting biological samples for use in the detection of genes and copy number variations for hereditary cancer, identification of hereditary risk associated with cancer and identification of predisposition to cancer.

Goods & Services

Medical testing services, namely, genetic testing and next generation sequencing for detection of genes and copy number variations for hereditary cancer, identification of hereditary risk associated with cancer and identification of predisposition to cancer.

Goods & Services

(1) Medical testing services, namely, genetic testing and next generation sequencing for detection of genes and copy number variations for hereditary cancer, identification of hereditary risk associated with cancer and identification of predisposition to cancer

Abstract

Provided herein is technology relating to the amplification-based detection of bisulfite-treated DNAs and particularly, but not exclusively, to methods and compositions for multiplex amplification of low-level sample DNA prior to further characterization of the sample DNA. The technology further provides methods for isolating DNA from blood or blood product samples, e.g., plasma samples.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips

Goods & Services

Diagnostic apparatus for the detection of cancer by detecting genes for hereditary cancer, identifying hereditary risk associated with cancer and identifying predisposition to cancer; Apparatus for collecting biological samples for use in the detection of cancer and pre-cancer for medical purposes by detecting genes for hereditary cancer, identifying hereditary risk associated with cancer and identifying predisposition to cancer; Containers for collecting biological samples for use in the detection of cancer and pre-cancer for medical purposes by detecting genes for hereditary cancer, identifying hereditary risk associated with cancer and identifying predisposition to cancer

Goods & Services

Medical testing services, namely, genetic testing and next generation sequencing test for diagnosis and treatment of cancer featuring detection of genes for hereditary cancer, identification of hereditary risk associated with cancer and identification of predisposition to cancer

Goods & Services

Preparations for detecting genetic predispositions for medical purposes, namely, hereditary cancer screening test comprised of molecular diagnostic reagents and assays for use in disease detection by detecting DNA, chromosomal changes, abnormalities or mutations for detection of genes for hereditary cancer, identifying hereditary risk associated with cancer and identifying predisposition to cancer; Reagents and assays for medical use; Medical diagnostic reagents; Medical diagnostic assays for use in disease detection and screening related to cancer

Abstract

Provided herein is technology for screening multiple types of cancer from a biological sample, and particularly, but not exclusively, to methods, compositions, and related uses for simultaneously detecting the presence of multiple types of cancer (e.g., liver cancer, esophageal cancer, lung cancer, ovarian cancer, pancreatic cancer, gastric cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, prostate cancer, renal cancer, and uterine cancer) from a biological sample (e.g., stool sample, tissue sample, organ secretion sample, CSF sample, saliva sample, blood sample, plasma sample or urine sample).

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer